Armelle Arnoux
Papers
1
Total Citations
2
H-Index
1
About
Dr. Armelle Arnoux is a clinical oncologist whose research focuses on innovative surgical and pharmacological strategies for renal cell carcinoma, particularly in nephron-sparing approaches. Her most cited work, the Phase II AXIPAN study (2016), investigates the use of axitinib, a potent VEGF receptor inhibitor, to downstage cT2a renal tumors to cT1 size, thereby enabling partial nephrectomy (PN) over radical nephrectomy (RN). This contribution is pivotal, as PN preserves long-term renal function and may improve overall survival, challenging the standard of care for larger organ-confined tumors. With 2 citations, the study highlights a targeted neoadjuvant strategy to expand surgical eligibility and reduce renal morbidity. Dr. Arnoux’s work bridges medical oncology and urology, emphasizing personalized treatment to optimize patient outcomes. Her research underscores a commitment to advancing minimally invasive, function-preserving therapies, making her a notable figure in renal cancer management.
Research Focus
Key Achievements
Top Papers
- 1